參考文獻(xiàn):
[1]PAULES C, SUBBARAO K. Influenza [J]. Lancet, 2017, 390 (10095): 697 - 708.
[2] Angie L, Besselaar T G, Daniels R S, et al. Global update on the susceptibility of human influenza viruses to
neuraminidase inhibitors and status of novel antivirals, 2016—2017[J]. Antivir Res, 2018(157): 38-46.
[3] Yacine A, Guy B. A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and
zanamivir[J]. Open Forum Infect Dis, 2017(3): x105.
[4] Abraham G M, Morton J B, Saravolatz L D. Baloxavir: A
novel antiviral agent in the treatment of influenza[J]. Clin Infect Dis, 2020, 71(7):1790-1794.
[5]潘辛梅,馬攀.基于 FAERS 數(shù)據(jù)庫對瑪巴洛沙韋安全警戒信號的挖掘與分析[J].中國抗生素雜志,2023,48(04):466-472.
[6]OMOTO S, SPERANZINI V, HASHIMOTO T, et al. Characterization of influenza virus variants induced by treatment with the
endonuclease inhibitor baloxavir marboxil [J]. Sci Rep, 2018, 8 (1): 9633.
[7]NOSHI T, KITANO M, TANIGUCHI K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent
endonuclease inhibitor of the influenza virus polymerase PA subunit [J]. Antiviral Res, 2018, 160 (1): 109 - 117.
[8]Treanor JJ , Hayden FG, V room an PS , et al . Efficacy and safety of oral neu ram in idase inhibitotor ose ltam ivir in treating
acute influenza. JAMA 2000 283: 1061-1065.
[9]王新敏,薛繼軍,陳富新.磷酸奧司他韋的臨床應(yīng)用進(jìn)展[J].中國處方藥,2014,12(03):125-127.
[10]李梅,張宏偉.磷酸奧司他韋(達(dá)菲)的藥理及不良反應(yīng)分析[J].中國社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè)半月刊),2008,(17):15.
[11]YANG T R. Baloxavir marboxil:the first cap-dependent endonuclease inhibitor for the treatment of influenza[J]. Ann
Pharmacother,2019,53(7):754-759.
[12]YOSHINO Y,KITAZAWA T,OTA Y. Clinical efficacy of baloxavir marboxil in the treatment of seasonal influenza in adult
patients:a prospective observational study[J]. Int J Gen Med,2020,13:735-741.
[13]吳越,陳啟庭,陳芳昭,卓超林,劉微,李學(xué)娟,陳澤彬.瑪巴洛沙韋治療流行性感冒的快速衛(wèi)生技術(shù)評估[J].中國藥
房,2023,34(19):2402-2408.